Form 4: Tarsus Pharmaceuticals Director Reports Stock Transaction
Insider Transaction (Form 4)
David E I Pyott, a Director of Tarsus Pharmaceuticals, Inc., reported multiple transactions in common stock on September 15, 2026.
Summary
- Option exercise/conversion: acquired 201 Common Stock on September 15, 2026; holds 9,575 after (Indirect).
- Option exercise/conversion: disposed of 201 Restricted Stock Units on September 15, 2026; holds 605 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
David E I Pyott — Director
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-15 | Option exercise/conversion | Common Stock | 201 | — | — | 9,575 |
| 2026-09-15 | Option exercise/conversion | Restricted Stock Units | 201 | — | — | 605 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-15 | Option exercise/conversion (201 shares) |
| 2026-09-15 | Option exercise/conversion (201 shares) |
Keywords
insider transaction, Form 4, TARS, Tarsus Pharmaceuticals, Inc., neutral, David E I Pyott
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.